UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 29, 2026

Aligos Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-39617

82-4724808

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification Number)

One Corporate Dr., 2nd Floor

South San Francisco, CA

94080

(Address of principal executive offices)

(Zip Code)

(800) 466-6059

(Registrant’s telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol

Name of each exchange

on which registered

Common Stock, $0.0001 par value per share

ALGS

The Nasdaq Stock Market LLC

(Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 29, 2026, the Board of Directors of Aligos Therapeutics, Inc. (the “Company”) appointed Nikhil Aneja as the Company’s Principal Accounting Officer, effective immediately. In this role, Mr. Aneja succeeds Lesley Ann Calhoun, who continues to serve as the Company’s Executive Vice President, Chief Operating Officer & Chief Financial Officer.

Mr. Aneja, age 49, has served as the Company’s Vice President, Finance since February 2024. From December 2022 to February 2024, Mr. Aneja served as Vice President, Corporate Controller at CareDx, Inc., a diagnostic company. Prior to that, Mr. Aneja served as Vice President, Finance and Accounting at Blade Therapeutics, Inc., a biopharmaceutical company, from May 2021 to October 2022, and as Executive Director, Global Corporate Controller at Global Blood Therapeutics, Inc., a biopharmaceutical company, from September 2016 to May 2021. He received his Bachelor of Commerce from the University of Delhi and is a Certified Public Accountant.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALIGOS THERAPEUTICS, INC.

Date: February 4, 2026

/s/ Lesley Ann Calhoun

Lesley Ann Calhoun

Executive Vice President, Chief Operating Officer & Chief Financial Officer

Aligos Therapeutics, Inc. 8-K